Oracle & APCO Help Advance Dermatology Research in Asian Markets

In recent years, the prevalence of chronic skin conditions such as atopic dermatitis (AD) and alopecia areata (AA) has been increasing within Asian populations. This trend is being driven by rapid urbanization, improved living standards, and climate change, especially in major metropolitan areas across Hong Kong, Singapore, and Taiwan. Understanding the rising burden of these skin conditions will be essential to improving patient outcomes, given the diverse epidemiological profiles, diagnostic criteria, and economic implications across different regions.

Oracle Life Sciences, in collaboration with advisory firm APCO, has published a new whitepaper, titled "Revolutionizing Skin Conditions: Cultivating Equity, Inclusion, and Access,” showing how health systems in these regions are applying a “person-centered” model in caring for these patients. This approach incorporates both the physical manifestations of these dermatological conditions and their biopsychosocial impacts. With input from key opinion leaders, patients, and healthcare payers, this whitepaper highlights the importance of innovation and multisectoral collaboration in transforming dermatology care.

AD, an inflammatory skin condition, and AA, an autoimmune disease that causes patchy hair loss, affect a disproportionately high amount of adults in Asia. Both conditions are exacerbated by systemic barriers to care, including a lack of healthcare access in some places, a lack of patient representation in developing clinical guidelines, and the financial burden posed by advanced therapies.

This whitepaper highlights the psychosocial distress AD and AA patients experience, including anxiety, depression, and social isolation due to the visibility of their symptoms, emphasizing the importance of psychological support alongside medical treatment.

The emergence of novel treatments, such as Janus Kinase (JAK) inhibitors, presents a promising avenue for patients. However, financial constraints often limit access, highlighting the need for improved insurance coverage and healthcare financing models. As healthcare systems evolve, fostering collaboration between healthcare providers, policymakers, and patient advocacy groups is critical to ensuring that advanced therapies are accessible to all.

Drawing on the comprehensive research conducted by Oracle Life Sciences, this whitepaper presents strategies for enhancing dermatology care in Hong Kong, Singapore, and Taiwan. The research recommends facilitating open discussions about treatment goals, addressing the emotional and financial burdens of chronic skin conditions, and expanding access to advanced therapies.

Oracle Life Sciences offers a comprehensive suite of solutions that streamline clinical trials, enhance safety and pharmacovigilance, and provide real-world evidence, thereby accelerating drug development and improving patient outcomes.